ALL, Besponsa, Leukemia, Merck
Inotuzumab ozogamicin is approved by the USFDA for pediatric patients with acute lymphoblastic leukemia
6th March 2024: Inotuzumab ozogamicin (Besponsa, Pfizer) has been granted approval by the Food and Drug Administration for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) ..
BALL, BALL Trials, CAR T Cell therapy trials, Clinical trials, Leukemia, Leukemia trials, Trials in China
Clinical trial recruitment for BALL CAR T-Cell therapy
16th March 2023: The treatment of cancer is being revolutionized by new immunotherapeutic drugs that target the microenvironment at the tumour site. T cells with chimeric antigen receptors (CAR) are being extensively researched ..
CAR - T Cell therapy, CART therapy, China CAR T Cell therapy, Leukemia, T Cell Leukemia
CAR T-Cell therapy for T-cell acute lymphoblastic leukaemia (T-ALL)
June 2021 : As per our resources, a hospital in China has developed CAR T-Cell therapy for T-cell acute lymphoblastic leukaemia (T-ALL). The expressing protein in this case is CD7. 5 patients have been tested with the therapy, and..